Dianthus Therapeutics, Inc. /DE/
DNTHDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
2dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
DNTH Earnings Report
EPS Est: $-0.93 | FQ end 2026-06
How DNTH's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DNTH103 | Phase 3 | Myasthenia Gravis, Generalized | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Dianthus Therapeutics, Inc. /DE/'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Dianthus Therapeutics, Inc. /DE/'s (DNTH) pipeline across Phase 3. Its lead program is DNTH103 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dianthus Therapeutics, Inc. /DE/'s next FDA catalyst?→
Dianthus Therapeutics, Inc. /DE/'s (DNTH) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DNTH biotech catalysts?→
Add DNTH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dianthus Therapeutics, Inc. /DE/'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.